Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 286

1.

Synergistic activities of tigecycline with clarithromycin or amikacin against rapidly growing mycobacteria in Taiwan.

Huang CW, Chen JH, Hu ST, Huang WC, Lee YC, Huang CC, Shen GH.

Int J Antimicrob Agents. 2013 Mar;41(3):218-23. doi: 10.1016/j.ijantimicag.2012.10.021. Epub 2013 Jan 9.

PMID:
23312605
2.
3.

[Drug sensitivity analysis of Mycobacterium chelonae and Mycobacterium abscessus and evaluation of Etest for susceptibility testing].

Gui J, Wang F, Hong CY, Li JL, Liang J.

Zhonghua Jie He He Hu Xi Za Zhi. 2013 Aug;36(8):567-71. Chinese.

PMID:
24252731
4.

High efficacy of clofazimine and its synergistic effect with amikacin against rapidly growing mycobacteria.

Shen GH, Wu BD, Hu ST, Lin CF, Wu KM, Chen JH.

Int J Antimicrob Agents. 2010 Apr;35(4):400-4. doi: 10.1016/j.ijantimicag.2009.12.008.

PMID:
20138481
5.

High prevalence of antimicrobial resistance in rapidly growing mycobacteria in Taiwan.

Yang SC, Hsueh PR, Lai HC, Teng LJ, Huang LM, Chen JM, Wang SK, Shie DC, Ho SW, Luh KT.

Antimicrob Agents Chemother. 2003 Jun;47(6):1958-62.

6.

Clinical outcome of Mycobacterium abscessus infection and antimicrobial susceptibility testing.

Huang YC, Liu MF, Shen GH, Lin CF, Kao CC, Liu PY, Shi ZY.

J Microbiol Immunol Infect. 2010 Oct;43(5):401-6. doi: 10.1016/S1684-1182(10)60063-1.

7.

In vitro evaluation of a new drug combination against clinical isolates belonging to the Mycobacterium abscessus complex.

Singh S, Bouzinbi N, Chaturvedi V, Godreuil S, Kremer L.

Clin Microbiol Infect. 2014 Dec;20(12):O1124-7. doi: 10.1111/1469-0691.12780. Epub 2014 Oct 3.

8.

In vitro activity of clarithromycin in combination with other antimicrobial agents against Mycobacterium abscessus and Mycobacterium massiliense.

Zhang Z, Lu J, Liu M, Wang Y, Zhao Y, Pang Y.

Int J Antimicrob Agents. 2017 Mar;49(3):383-386. doi: 10.1016/j.ijantimicag.2016.12.003. Epub 2017 Feb 7.

PMID:
28188830
9.

Nontuberculous mycobacterial ocular infections--comparing the clinical and microbiological characteristics between Mycobacterium abscessus and Mycobacterium massiliense.

Chu HS, Chang SC, Shen EP, Hu FR.

PLoS One. 2015 Jan 12;10(1):e0116236. doi: 10.1371/journal.pone.0116236. eCollection 2015.

10.

Evaluation of antimicrobial susceptibilities of rapidly growing mycobacteria by Sensititre RAPMYCO panel.

Cavusoglu C, Gurpinar T, Ecemis T.

New Microbiol. 2012 Jan;35(1):73-6. Epub 2012 Jan 10.

11.

Antimicrobial resistance of rapidly growing mycobacteria in western Taiwan: SMART program 2002.

Huang TS, Lee SS, Hsueh PR, Tsai HC, Chen YS, Wann SR, Leu HS, Ko WC, Yan JJ, Yuan SZ, Chang FY, Lu JJ, Wang JH, Wang HK, Liu YC.

J Formos Med Assoc. 2008 Apr;107(4):281-7.

12.

In Vitro Antimicrobial Susceptibility of Nontuberculous Mycobacteria in Iran.

Heidarieh P, Mirsaeidi M, Hashemzadeh M, Feizabadi MM, Bostanabad SZ, Nobar MG, Hashemi Shahraki A.

Microb Drug Resist. 2016 Mar;22(2):172-8. doi: 10.1089/mdr.2015.0134. Epub 2015 Oct 15.

PMID:
26468990
13.

Multisite reproducibility of results obtained by the broth microdilution method for susceptibility testing of Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum.

Woods GL, Bergmann JS, Witebsky FG, Fahle GA, Wanger A, Boulet B, Plaunt M, Brown BA, Wallace RJ Jr.

J Clin Microbiol. 1999 Jun;37(6):1676-82.

14.

Absence of a functional erm gene in isolates of Mycobacterium immunogenum and the Mycobacterium mucogenicum group, based on in vitro clarithromycin susceptibility.

Brown-Elliott BA, Hanson K, Vasireddy S, Iakhiaeva E, Nash KA, Vasireddy R, Parodi N, Smith T, Gee M, Strong A, Barker A, Cohen S, Muir H, Slechta ES, Wallace RJ Jr.

J Clin Microbiol. 2015 Mar;53(3):875-8. doi: 10.1128/JCM.02936-14. Epub 2015 Jan 7.

15.

Species identification of Mycobacterium abscessus subsp. abscessus and Mycobacterium abscessus subsp. bolletii using rpoB and hsp65, and susceptibility testing to eight antibiotics.

Nie W, Duan H, Huang H, Lu Y, Bi D, Chu N.

Int J Infect Dis. 2014 Aug;25:170-4. doi: 10.1016/j.ijid.2014.02.014. Epub 2014 Jun 13.

16.

In vitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease.

van Ingen J, Totten SE, Helstrom NK, Heifets LB, Boeree MJ, Daley CL.

Antimicrob Agents Chemother. 2012 Dec;56(12):6324-7. doi: 10.1128/AAC.01505-12. Epub 2012 Oct 1.

17.

Clofazimine Prevents the Regrowth of Mycobacterium abscessus and Mycobacterium avium Type Strains Exposed to Amikacin and Clarithromycin.

Ferro BE, Meletiadis J, Wattenberg M, de Jong A, van Soolingen D, Mouton JW, van Ingen J.

Antimicrob Agents Chemother. 2015 Dec 7;60(2):1097-105. doi: 10.1128/AAC.02615-15. Print 2016 Feb.

18.

[The analysis of species identification and susceptibility testing of Mycobacterium abscessus].

Nie W, Duan H, Huang H, Lu Y, Chu N.

Zhonghua Jie He He Hu Xi Za Zhi. 2014 Jul;37(7):517-21. Chinese.

PMID:
25262693
19.

CNS infections caused by Mycobacterium abscessus complex: clinical features and antimicrobial susceptibilities of isolates.

Lee MR, Cheng A, Lee YC, Yang CY, Lai CC, Huang YT, Ho CC, Wang HC, Yu CJ, Hsueh PR.

J Antimicrob Chemother. 2012 Jan;67(1):222-5. doi: 10.1093/jac/dkr420. Epub 2011 Oct 6.

PMID:
21980068
20.

The drug susceptibility profile and inducible resistance to macrolides of Mycobacterium abscessus and Mycobacterium massiliense in Korea.

Kim SY, Kim CK, Bae IK, Jeong SH, Yim JJ, Jung JY, Park MS, Kim YS, Kim SK, Chang J, Kang YA.

Diagn Microbiol Infect Dis. 2015 Feb;81(2):107-11. doi: 10.1016/j.diagmicrobio.2014.10.007. Epub 2014 Oct 25.

PMID:
25467784

Supplemental Content

Support Center